
    
      OBJECTIVES:

      To define objective response, time to progression and safety of Simvastatin in Waldenstr√∂m's
      Macroglobulinemia.

      STATISTICAL DESIGN:

      For this phase II study, a single-stage design is used to evaluate the efficacy of
      Simvastatin. With a target enrollment of 30 participants, the 95% exact confidence bounds
      surrounding the response estimate will be no wider than +/- 19%.
    
  